Clinical Trial Update: Antibody and Safety Study of 6 Doses of NicVAX in Smokers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports completion of a study evaluating six doses of NicVAX, Nabi Biopharmaceuticals' nicotine vaccine, in smokers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• NicVAX (nicotine vaccine)

Snippet

Sponsor: Nabi Biopharmaceuticals | Conditions: Smoking | Phase 1, Phase 2 | Status: COMPLETED